Caribou Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Caribou Biosciences, Inc.
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.
Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.
Appointments: C4 Therapeutics, ORIC Pharma, CytRx, Audentes, Atara, Caribou, Sangamo And Pliant Announce Changes
New appointments announced over the past week include new CEOs at C4 Therapeutics and ORIC pharma, COO at CytRx, President at Audentes, global R&D head at Atara, CBO at Caribou, CTO at Sangamo, and chairman at Pliant.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools